From: Study partners should be required in preclinical Alzheimer’s disease trials
Against dyadic enrollment | In favor of dyadic enrollment |
---|---|
• The requirement is a barrier to enrollment | • Study partners may be necessary to ensure participant safety, assisting in overcoming distress related to biomarker disclosure |
• Study partners are not needed to ensure adequate informed consent since participants are cognitively normal, autonomous decision makers | • Individuals who lack a study partner may be at greatest risk for catastrophic reaction, including suicide |
• The requirement may introduce novel risks related to confidentiality/privacy | • The study partner can provide support that will mitigate stigma |
• The requirement may introduce the risk of stigma to participants | • The requirement may maximize participant retention |
• The requirement may optimize data integrity | |
• Scales to measure patient function require study partners | |
• Involving study partners in trials may best instruct an as yet undefined practice |